Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNEPi: Entresto in HFpEF
NCT03506412Phase 4Completed
- Sponsor
- Mayo Clinic
- Start
- Jun 2018
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sacubitril + valsartan in heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by Mayo Clinic. Primary endpoints: Change in Plasma N-terminal Proatrial Natriuretic Peptide at 5 weeks, Change in Plasma N-terminal Pro B-type Natriuretic Peptide at 5 weeks and 2 more. Started Jun 2018; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT03506412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03506412.